Cargando…
Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses
Nirmatrelvir is the main component of Paxlovid, an oral antiviral drug approved for the treatment of COVID-19 caused by SARS-COV-2 infection. Nirmatrelvir targets the main protease (M(pro)), which is substantially conserved among different coronaviruses. Here, our molecular docking analysis indicate...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Authors. Published by Elsevier B.V.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925195/ https://www.ncbi.nlm.nih.gov/pubmed/36791846 http://dx.doi.org/10.1016/j.antiviral.2023.105555 |